王继闯 助理研究员
硕士生导师
联系邮箱：wjchuang[email protected]
个人简介
王继闯，助理研究员，硕士生导师。福州大学生物化工专业获博士学位。福建省细胞生物学和转化医学学会理事，福建省药理学会肿瘤药理专业委员会委员。累计以第一作者或通讯作者（含共同）在Pharmacological Research、Cancer Letters等期刊发表SCI论文11篇。
研究领域
1.肿瘤药物治疗与耐药
2.肿瘤转移分子机制
主持/参与的项目
1.福建省科技创新联合资金项目，基于SULF2/β-catenin信号通路探讨肝癌ATRA耐药性的作用机制，2024.12-2027.12，主持
2.福建省科技创新联合资金项目，PLAG1/Thy-1信号轴参与肝癌Regorafenib耐药的作用机制研究，2021.8-2024.8，主持
3.福建省自然科学基金面上项目，COL5A2调节EMT介导肝癌耐药细胞转移及VM形成的作用机制研究, 2020-11-2023-11，主持
4.福建省科技创新联合资金项目，低氧微环境下Pin1对肝癌细胞化疗耐药的作用及机制研究，2016.9-2019.9，主持
5.福建省自然科学基金青年创新项目，异构酶Pin1介导上皮-间质转化调控肝细胞癌的侵袭转移研究，2016.4-2019.4，主持
科研成果
1. Shaoqin Zhang#, Xuezhen Xue#, Fengdan Chen, Yahan Yang, Nan Zhang, Yan Chen, Wenda Wu, Jichuang Wang*, Ning Zheng*. COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma, Acta Biochimica et Biophysica Sinica, 2024, 56(7): 997-1010. (IF：3.4，中科院2区)
2. Wenda Wu#, Xuezhen Xue#, Yan Chen, Ning Zheng*, Jichuang Wang*. Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies, Pharmacological Research, 2022, 184: 106456. (IF：9.3，中科院1区)
3. Nan Zhang, Shaoqin Zhang, Wenda Wu, Wenxian Lu, Mingting Jiang, Ning Zheng, Jing Huang, Long Wang, Hekun Liu, Min Zheng, Jichuang Wang*. Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT, Molecular Carcinogenesis, 2021, 60(2): 151-163. (IF：5.1，中科院2区)
4. Ning Zheng, Shaoqin Zhang, Wenda Wu, Nan Zhang, Jichuang Wang*. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma, Pharmacological Research, 2021, 166: 105507. (IF：10.3，中科院1区)
5. Jichuang Wang#, Nan Zhang#, Qi Han, Wenxian Lu, Long Wang, Dayun Yang, Min Zheng, Zhenzhen Zhang, Hekun Liu, Tae Ho Lee, Xiao Zhen Zhou, Kun Ping Lu*, Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway, Cancer Letters, 2019, 444: 82–93. (IF：7.4，中科院1区)
6. Jichuang Wang#, Xin-Hua Liao#, Min Zheng, Dayun Yang, Xiao Zhen Zhou, Hekun Liu*, Kun Ping Lu*, The roles of the unique prolyl isomerase Pin1 in cancer-related viral and bacterial infections, Current Molecular Medicine, 2016, 16(9): 793-802. (IF：2.3，中科院2区)
7. Jichuang Wang#, Jianzhong Chen#, Yewei Zhu, Ning Zheng, Jian Liu, Yingying Xiao, Yusheng Lu, Haiyan Dong, Jingjing Xie, Suhong Yu, Jingwei Shao, Lee Jia*, In Vitro and in Vivo Efficacy and Safety Evaluation of Metapristone and Mifepristone as Cancer Metastatic Chemopreventive Agents, Biomedicine and Pharmacotherapy, 2016, 78: 291-300. (IF：2.8，中科院3区)
8. Jichuang Wang#, Zhou Jiang#, Liping Xiang, Yuanfang Li, Minrui Ou, Xiang Yang, Jingwei Shao*, Yusheng Lu, Lifeng Lin, Jianzhong Chen, Yun Dai, Lee Jia*, Synergism of Ursolic Acid Derivative US597 with 2-deoxy-D-glucose to Preferentially Induce Tumor Cell Death by Dual-targeting of Apoptosis and Glycolysis, Scientific Reports, 2014, 4: 5006. (IF：5.6，中科院2区)
9. Jichuang Wang#, Jianzhong Chen#, Liyuan Wan, Jingwei Shao*, Yusheng Lu, Yewei Zhu, Minrui Ou, Suhong Yu, Haijun Chen, Lee Jia*, Synthesis, Spectral Characterization, and in Vitro Cellular Activities of Metapristone, a Potential Cancer Metastatic Chemopreventive Agent Derived from Mifepristone (RU486), The AAPS Journal, 2014, 16(2): 289-298. (IF：3.8，中科院2区)
10. Jianzhong Chen#, Jichuang Wang#, Jingwei Shao, Yu Gao, Jianguo Xu, Suhong Yu, Zhenhua Liu, Lee Jia*. The Unique Pharmacological Characteristics of Mifepristone (RU486): From Terminating Pregnancy to Preventing Cancer Metastasis. Med Res Rev, 2014, 34: 979-1000. (IF：8.1，中科院1区)
11. Jianzhong Chen#, Jichuang Wang#, Yu Gao, Rongjie Zeng, Zhou Jiang, Yewei Zhu, Jingwei Shao, Lee Jia*. A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486). J Pharm Biomed Anal, 2014, 95: 158-163. (IF：2.8，中科院3区)
（更新于2025年7月）
